Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis

MLA

Teng-Kai Yang, et al. “Efficacy and Safety of Combined Targeted Therapy and Immunotherapy versus Targeted Monotherapy in Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.” BMC Cancer, vol. 22, no. 1, Oct. 2022, pp. 1–8. EBSCOhost, https://doi.org/10.1186/s12885-022-10174-6.

APA

Teng-Kai Yang, Ya-Fang Yu, Chiao-Ling Tsai, Hsing-Ju Li, Po-Sheng Yang, Kai-Wen Huang, & Jason Chia-Hsien Cheng. (2022). Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis. BMC Cancer, 22(1), 1–8. https://doi.org/10.1186/s12885-022-10174-6

Chicago

Teng-Kai Yang, Ya-Fang Yu, Chiao-Ling Tsai, Hsing-Ju Li, Po-Sheng Yang, Kai-Wen Huang, and Jason Chia-Hsien Cheng. 2022. “Efficacy and Safety of Combined Targeted Therapy and Immunotherapy versus Targeted Monotherapy in Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.” BMC Cancer 22 (1): 1–8. doi:10.1186/s12885-022-10174-6.